CN113939521A - 作为cxcr4调节剂的咪唑啉衍生物 - Google Patents

作为cxcr4调节剂的咪唑啉衍生物 Download PDF

Info

Publication number
CN113939521A
CN113939521A CN202080039433.1A CN202080039433A CN113939521A CN 113939521 A CN113939521 A CN 113939521A CN 202080039433 A CN202080039433 A CN 202080039433A CN 113939521 A CN113939521 A CN 113939521A
Authority
CN
China
Prior art keywords
alkyl
methyl
imidazol
thio
thiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080039433.1A
Other languages
English (en)
Chinese (zh)
Inventor
N·贝卡杜尔贝纳蒂亚
M·罗德罗
J-P·赫伯瓦尔
N·皮特兰科斯塔
N·史密斯
A·巴里
J·卡苏
S·梅耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Cite
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Paris filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CN113939521A publication Critical patent/CN113939521A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080039433.1A 2019-03-29 2020-03-27 作为cxcr4调节剂的咪唑啉衍生物 Pending CN113939521A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305409.5 2019-03-29
EP19305409 2019-03-29
PCT/EP2020/058728 WO2020201096A1 (en) 2019-03-29 2020-03-27 Imidazoline derivatives as cxcr4 modulators

Publications (1)

Publication Number Publication Date
CN113939521A true CN113939521A (zh) 2022-01-14

Family

ID=66102603

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080039433.1A Pending CN113939521A (zh) 2019-03-29 2020-03-27 作为cxcr4调节剂的咪唑啉衍生物

Country Status (12)

Country Link
US (1) US20220144853A1 (https=)
EP (1) EP3947394A1 (https=)
JP (1) JP2022527641A (https=)
KR (1) KR20210146318A (https=)
CN (1) CN113939521A (https=)
AU (1) AU2020255206A1 (https=)
BR (1) BR112021019344A8 (https=)
CA (1) CA3132527A1 (https=)
IL (1) IL286399A (https=)
MX (1) MX2021011599A (https=)
SG (1) SG11202109671WA (https=)
WO (1) WO2020201096A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1393228A (en) * 1972-09-28 1975-05-07 Searle & Co 2-2-2-methyl-5-nitro-1-imidazolyl-ethyl-2-thiopseudoureas and related compounds
US20050026916A1 (en) * 2003-07-21 2005-02-03 Aventis Pharmaceuticals Inc. Heterocyclic compounds as P2X7 ion channel blockers
WO2017216368A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE565868A (https=) 1957-03-21
US4205071A (en) 1976-05-14 1980-05-27 Smith Kline & French Laboratories Limited Pharmaceutical compositions having immunosuppressant activity and methods therefor
US4349674A (en) 1978-12-18 1982-09-14 American Home Products Corporation Quinoalinyl esters of carbamimidothioic acids
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US20040254221A1 (en) 2001-09-28 2004-12-16 Toru Yamazaki Novel Nitrogenous Compound and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1393228A (en) * 1972-09-28 1975-05-07 Searle & Co 2-2-2-methyl-5-nitro-1-imidazolyl-ethyl-2-thiopseudoureas and related compounds
US20050026916A1 (en) * 2003-07-21 2005-02-03 Aventis Pharmaceuticals Inc. Heterocyclic compounds as P2X7 ion channel blockers
WO2017216368A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
CA: "CAS登记号：1024259-89-9", STN-REGISTRY数据库, 1 January 2008 (2008-01-01) *
CA: "CAS登记号：1024367-29-0", STN-REGISTRY数据库, 1 January 2008 (2008-01-01) *
CA: "CAS登记号：1171815-32-9、1171669-06-9", STN-REGISTRY数据库, 2 August 2009 (2009-08-02) *
CA: "CAS登记号：1514199-61-1", STN-REGISTRY数据库, 8 January 2014 (2014-01-08) *
CA: "CAS登记号：1623930-36-8", STN-REGISTRY数据库, 21 September 2014 (2014-09-21) *
CA: "CAS登记号：1624027-61-7", STN-REGISTRY数据库, 21 September 2014 (2014-09-21) *
CA: "CAS登记号：1624254-33-", STN-REGISTRY数据库, 22 September 2014 (2014-09-22) *
CA: "CAS登记号：1780146-10-", STN-REGISTRY数据库, 14 June 2015 (2015-06-14) *
CA: "CAS登记号：1780146-16-8", STN-REGISTRY数据库, 14 June 2015 (2015-06-14) *
CA: "CAS登记号：1780430-06-9", STN-REGISTRY数据库, 14 June 2015 (2015-06-14) *
CA: "CAS登记号：1783358-43-9", STN-REGISTRY数据库, 18 June 2015 (2015-06-18) *
CA: "CAS登记号：1784838-54-5", STN-REGISTRY数据库, 21 June 2015 (2015-06-21) *
CA: "CAS登记号：1785092-63-8", STN-REGISTRY数据库, 21 June 2015 (2015-06-21) *
CA: "CAS登记号：354550-70-2", STN-REGISTRY数据库, 4 September 2001 (2001-09-04) *
CA: "CAS登记号：904553-80-6", STN-REGISTRY数据库, 25 August 2006 (2006-08-25) *
CA: "CAS登记号：930525-42-1", STN-REGISTRY数据库, 17 April 2007 (2007-04-17) *
CA: "CAS登记号：952014-08-3", STN-REGISTRY数据库, 30 October 2007 (2007-10-30) *
CA: "CAS登记号：952014-08-3、1216705-77-9", STN-REGISTRY数据库, 5 April 2010 (2010-04-05) *

Also Published As

Publication number Publication date
WO2020201096A1 (en) 2020-10-08
CA3132527A1 (en) 2020-10-08
MX2021011599A (es) 2021-12-10
BR112021019344A8 (pt) 2022-12-06
IL286399A (en) 2021-10-31
AU2020255206A1 (en) 2021-10-14
KR20210146318A (ko) 2021-12-03
BR112021019344A2 (https=) 2021-12-14
EP3947394A1 (en) 2022-02-09
JP2022527641A (ja) 2022-06-02
US20220144853A1 (en) 2022-05-12
SG11202109671WA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US12076408B2 (en) ASGPR-binding compounds for the degradation of extracellular proteins
CA3161878A1 (en) Irak degraders and uses thereof
EP3630775B1 (en) 6-5 FUSED RINGS AS C5a INHIBITORS
CN119751465A (zh) 螺环化合物
CA3086763A1 (en) Irak degraders and uses thereof
JP7200120B2 (ja) Ｍｋ２阻害剤として有用なヘテロアリール化合物
CZ20004339A3 (cs) Nové 2-alkylem substituované imidazolové sloučeniny
TW202115082A (zh) 作為ａ２ａ／ａ２ｂ抑制劑之三唑并嘧啶
CA3106513A1 (en) Heteroaromatic compounds as vanin inhibitors
CA2802808A1 (en) Purine compounds selective for pi3k p110 delta, and methods of use
CN111032658A (zh) 作为C5a抑制剂的5-5稠合环类
EP2474543A1 (en) Therapeutic agent for mood disorders
US20210040066A1 (en) Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
US20260078103A1 (en) Isoquinolones as pi3k inhibitors
CN116568675A (zh) 作为cxcr4调节剂的环状异硫脲衍生物
KR102288246B1 (ko) 라파마이신 신호전달 경로 저해제의 기계적 표적 및 이의 치료학적 적용
CN113939521A (zh) 作为cxcr4调节剂的咪唑啉衍生物
HK40026727A (en) 6-5 fused rings as c5a inhibitors
HK40026727B (en) 6-5 fused rings as c5a inhibitors
HK1173144A (en) Therapeutic agent for mood disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Paris France

Applicant after: University of Western dais, Paris

Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Address before: Paris France

Applicant before: University of Paris

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220114